In the rheumatoid arthritis subgroup (n = 96), exposure to TNF inhibitors was associated with greater risk of developing any inflammatory demyelinating or nondemyelinating CNS events (adjusted OR, 4.82; 95% CI, 1.62-14.36; P = .005) (Table 4). The gene discussed is TNF; the disease is rheumatoid arthritis.